PDCD1 and non-small cell lung carcinoma: One of the first clinical evidences of advanced squamous non-small cell lung cancer (NSCLC) with severe thrombocytopenia showed dramatic improvement after first-line treatment with pembrolizumab (anti-PD-1 monoclonal antibody (mAb)) and autologous CIK cells [10].